Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.

Clinical lung cancer - 1 Sept 2020

Marmarelis Melina E, Langer Corey J

Abstract excerpt

Non-small-cell lung cancer is a major cause of cancer morbidity and mortality worldwide, and these patients have traditionally had a grim prognosis. As our understanding of actionable molecular aberrations that drive oncogenesis has grown, so too has the number of available therapies with improved outcomes in selectively targeted patient populations. This review provides an overview of the clinical response of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 32505631
DOI: 10.1016/j.cllc.2020.01.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.PMID 32505631Read ↗

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung CancerSemantic proximity Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

Future Directions in the Management of Non-Small Cell Lung Cancer Harboring Driver Mutations.Semantic proximity Read ↗

New Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.